Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly

Hua, Shih-Che; Yan, Yuan-Horng; Chang, Tien–Chun

doi:10.1530/eje.1.02292

Cited by 64 publications

(61 citation statements)

References 23 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies showed that QoL is severely affected in acromegalic patients, even in those patients with controlled disease [24][25][26][27][28]. In our study, the median AcroQoL total score seems quite low compared to other studies.…”

Section: Discussioncontrasting

confidence: 73%

Acromegaly is associated with higher frequency of female sexual dysfunction: experience of a single center

et al. 2013

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 73%

Acromegaly is associated with higher frequency of female sexual dysfunction: experience of a single center

et al. 2013

View full text Add to dashboard Cite

“…Further, our study did not rely only on the disease-specific AcroQoL but also on generic scales measuring HR-QoL and fatigue. A previous study by Hua et al (20) showed that in the group of patients with disease control, treatment with Lanreotide was associated with worse AcroQoL scores. This study was small, comparing 13 patients on Lanreotide treatment with 17 patients with cure of disease.…”

Section: Discussionmentioning

confidence: 95%

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Postma

Netea‐Maier²,

Berg³

et al. 2012

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To assess the influence of long-acting somatostatin analogs (SSTA) after initial pituitary surgery on long-term health-related quality of life (HR-QoL) in relation to disease control in patients with acromegaly. Design: This is a cross-sectional study in two tertiary referral centers in The Netherlands. Patients and methods: One hundred and eight patients with acromegaly, in whom transsphenoidal (nZ101, 94%) or transcranial (nZ7, 6%) surgery was performed. Subsequently, 46 (43%) received additional radiotherapy and 41 (38%) were on postoperative treatment with SSTA because of persistent or recurrent disease at the time of study. All subjects filled in standardized questionnaires measuring HR-QoL. Disease control at the time of study was assessed by local IGF1 SDS. Results: IGF1 SDS were slightly higher in patients treated with SSTA in comparison with patients without use of SSTA (0.85G1.52 vs 0.25G1.21, PZ0.026), but the percentage of patients with insufficient control (IGF1 SDS O2) was not different (17 vs 9%, PZ0.208). Patients using SSTA reported poorer scores on most subscales of the RAND-36 and the acromegaly QoL and on all subscales of the multidimensional fatigue inventory-20. A subgroup analysis in patients with similar IGF1 levels (SSTAC, nZ26, IGF1 SDS 0.44G0.72 vs SSTAK, nZ44, IGF1 SDS 0.41G0.65) revealed worse scores on physical functioning, physical fatigue, reduced activity, vitality, and general health perception across all HR-QoL questionnaires in patients treated with SSTA. Conclusion: QoL is impaired in association with the need for prolonged postoperative therapy by SSTA in patients with acromegaly despite similar IGF1 levels.

show abstract

“…All acromegalic patients treated by long-acting forms of somatostatin analogs had monthly injections done by nurses of their neighborhood. Recently, a crosssectional study including 52 patients with treated acromegaly showed no difference in the AcroQol scores between controlled and uncontrolled groups (28). However, in the biochemically controlled group, patients treated with i.m.…”

Section: Discussionmentioning

confidence: 98%

Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance

Matta¹,

Couture²,

Cazals³

et al. 2008

European Journal of Endocrinology

102

View full text Add to dashboard Cite

Introduction: Acromegaly, a chronic disease caused by GH/IGF-I excess, has a major impact on quality of life (QoL). Objective: To evaluate QoL of acromegalic patients in relation to control status of the disease. Design and methods: Single center observational study including 93 patients with acromegaly recruited to complete QoL questionnaire (AcroQol). QoL was evaluated at least 3 months after surgery and/or medical treatment. Patients were divided into two groups: controlled (I) and uncontrolled (II) according to the latest consensus acromegaly 'control' criteria and further subdivided into four subgroups according to the previous pituitary adenoma surgery (Ib and IIb) or without surgery (Ia and IIa). Results: Mean GH (0.81G0.47 ng/ml) and IGF-I (195G71 ng/ml) values in group I were significantly lower than in group II (GH, 7.01G12.05 ng/ml and IGF-I, 513G316 ng/ml; P!0.001). There was no difference in total AcroQol score, physical, or psychological scales between groups I and II. However, when adjusted to age and disease duration since diagnosis, patients of group I (63G20%) showed an improved psychological subscale appearance than those of group II (58G17%; PZ0.035). In group II, IGF-I level was lower after surgery (IIaZ588G353, IIbZ410G225 ng/ml; P!0.038), and psychological subscale appearance was significantly better in subgroup IIb (64.9G18.1%) than in subgroup IIa who had medical treatment (53.9G14.3%; PZ0.009). Conclusion: QoL is severely impaired in acromegalic patients. Control of GH/IGF-I excess by surgery or medical treatment seems to have a positive impact on psychological subscale appearance.

show abstract

Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly

Cited by 64 publications

References 23 publications

Acromegaly is associated with higher frequency of female sexual dysfunction: experience of a single center

Acromegaly is associated with higher frequency of female sexual dysfunction: experience of a single center

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance

Contact Info

Product

Resources

About